Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
to grant proposals, and present findings at international conferences. What you bring: PhD (or near completion) in Bioinformatics, Computational Biology, Data Science, Statistical Genomics, or related field
-
research programme at King’s, focussed on establishing a competitive research niche and positioning them to apply for intermediate-level post-doctoral fellowships to consolidate their careers, from Research
-
and beyond. Candidate Profile We welcome applicants with diverse backgrounds in experimental or computational biology who are excited by pioneering research directions. Qualifications PhD in molecular
-
projects that leverage our optical expertise to probe brain function Preferred Qualifications & Expertise: PhD in neuroscience, bioengineering, computational biology, or related field At least one strong
-
Research Fellow (Fusion Shielding Materials) - School of Metallurgy and Materials - 105638 - Grade 7
a framework for the role. Person Specification or Required Knowledge, Skills, Qualifications, Experience Hold a PhD (or one near to completion) in a relevant area, such as Fusion Energy, Nuclear
-
Supervise students on research-related work and provide guidance to PhD students where appropriate to the discipline Contribute to developing new computational models, techniques and methods Undertake
-
* Contribute to the supervision of PhD students and junior researchers Your Profile: * PhD in Bioinformatics, Computational Biology, Systems Biology, Biostatistics, or a related field – (Doctoral degree should
-
organoids will be plus. Dry lab: Highly motivated candidates with a PhD/MD degree in bioinformatics, genome science, systems biology, biomedical informatics, computational biology, machine learning, data
-
, pharmacy, biotechnology or bioengineering. Open to PhD students, PhD, Post-Doc and residents. Permanent positions such as Professors cannot apply. For the entire duration of the grant, applicants must be
-
oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor prognosis, and this clinic